Skip Navigation

Division of Allergy, Immunology, and Transplantation (DAIT)

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Cooperative Study Group for Autoimmune Disease Prevention

Formation and History

The Cooperative Study Group for Autoimmune Disease Prevention (CSGADP) was established in 2001 as a collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on Type 1 diabetes. The initial network of five cooperative agreements was funded by NIAID, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) Office for Research in Women’s Health, and the JDRF. In 2012, the Study Group was renewed through RFA AI11-034 with the award of seven 5-year cooperative agreements.

Mission

The mission of CSGADP is to engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease. The specific goals enunciated in pursuit of this mission are:

  • Identify common and disease-specific mechanisms of autoimmunity that can lead to novel pathways and methods to predict autoimmune disease and prevent its development
  • Connect markers of risk for autoimmune disease to alterations in immune function
  • Advance our understanding of genetic and environmental risk for autoimmune disease
  • Foster development of novel tools and approaches to the study of autoimmune disease risk, early pathogenesis, and onset of clinically apparent disease
  • Improve visibility and foster support for understanding early events and pathways toward prevention for systemic autoimmunity

Composition

The current Study Group includes the following cooperative agreements and principal investigators (links are to non-federal websites):

  • Dr. Paul Bollyky, “Extracellular matrix and immune regulation in autoimmune diabetes,” Stanford University
  • Dr. Jane Buckner, “Defining the role of altered cytokine signaling pathways on autoimmunity,” Benaroya Research Institute
  • Dr. David Hafler and Dr. Kevan Herold, “The role of the innate immune system on Treg reprogramming in human autoimmune diseases,” Yale University
  • Dr. Michael Holers, “Early targets for antigen-specific tolerance induction for preclinical rheumatoid arthritis,” University of Colorado Denver
  • Dr. Judith James, “Understanding early events in lupus autoimmunity to aid prevention,” Oklahoma Medical Research Foundation
  • Dr. Nora Sarvetnick, “Cytokine receptor populations in human autoimmune diabetes,” University of Nebraska Medical Center
  • Dr. Matthias von Herrath, “Assessment of cytokines in human islets from patients with diabetes,” La Jolla Institute for Allergy and Immunology

All of these principal investigators sit on the Group’s Steering Committee, with Dr. Buckner serving as Chair. NIH representatives to the Steering Committee include Beena Akolkar (NIDDK) and Thomas Esch (NIAID).

Innovative Projects

CSGADP Innovative Projects

The Steering Committee of the CSGADP has access to an Infrastructure and Opportunities Fund to support pilot projects of up to $75,000 for 1 year. Projects that are aligned with the mission of the CSGADP to engage in scientific discovery that significantly advances knowledge for the primary prevention and regulation of human autoimmune disease will be given priority. Specific areas of emphasis include

  • Identify common and disease-specific mechanisms of autoimmunity that can lead to novel pathways and methods to predict autoimmune disease and prevent its development
  • Connect markers of risk for autoimmune disease to alterations in immune function
  • Advance our understanding of genetic and environmental risk for autoimmune disease
  • Foster development of novel tools and approaches to the study of autoimmune disease risk, early pathogenesis, and onset of clinically apparent disease

Projects eligible for discretionary fund support should be novel, exciting, high-risk and focused on research into the etiology and immune mechanisms of human autoimmune disease. Projects that employ human systems or materials are preferred, but animal studies that can clearly be translated to human settings will be considered. Pilot proposals should be 1 year in length with a total direct cost budget of up to $75,000.

Potential applicants should contact a member of the Steering Committee for guidance and assistance (listed above). All proposals should include a 2-page research plan, NIH biosketch for key personnel, and a proposed budget (inclusive of direct and indirect costs: use of standard NIH budget pages is acceptable). The research plan should include specific aims, a statement of significance in relation to the goal of the CSGADP, innovation, feasibility, research methods, and a proposed timeline.  Preliminary data is not required for pilot proposals. The next date for submission of proposals is September 15, 2013.  To submit your proposal please email Wendy Kliment at Benaroya Research Institute.

Last Updated July 24, 2013